Attendee search 

Cro

diagnostics

healthcare investment

Mabwell, founded in 2017 in Zhangjiang District of Shanghai, is an innovation-based bio-pharmaceutical company with 9 biomedical R&D and manufacturing subsidiaries and a strong, diverse and experienced technical team under its wing. With its world class high-throughput antibody drug discovery platform, well-established pharmaceutical research system and mature process development, the company is dedicated to the R&D and manufacturing of therapeutic monoclonal antibodies, long acting recombinant protein and other new macromolecular drugs. Currently, 30 different drugs for tumor, autoimmunity, infection resistance and ophthalmology are being developed at various stages, among which 1 is cleared for production and 6 are in clinical research with 4 in key clinical stage. Guided by an innovation-driven strategy, the company has actively pushed for commercialization with a production facility built in line with both Chinese and Western GMP standards already up and running in Taizhou, Jiangsu province. Another large-scale industrial base in Shanghai is under construction. The first drug variety will be on the market in 2020 and the number will go up to 4 (or more) in 2023, Mabwell closed series A financing of 1.97 Billion Yuan at April, 2020, demonstrating the company’s ambition to become a leading bio-pharmaceutical enterprise in China.

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.

Founded in March 2017, IASO BIO is engaged in the development and industrialization of tumor cell immunotherapy drugs. Launched in Nanjing Biotech and Pharmaceutical Valley, the company has a total of 7,000㎡ of R&D platform and GMP pilot platform, and almost 10,000㎡ of commercial space in Nanjing. It also has a 1,750㎡ R&D platform in Zhangjiang Hi-tech Park ( Shanghai) and a global R&D center of approximately 57,000 square meters under construction in Shanghai Pilot Free Trade Zone. The company currently employs 350 staff.

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.